Aby J. Mathew - Jan 4, 2022 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
EVP & Chief Scientific Officer
Signature
/s/ Aby J. Mathew
Stock symbol
BLFS
Transactions as of
Jan 4, 2022
Transactions value $
-$595,095
Form type
4
Date filed
1/6/2022, 07:00 PM
Previous filing
Dec 30, 2021
Next filing
Feb 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $14K +10K +4.85% $1.40* 216K Jan 4, 2022 Direct
transaction BLFS Common Stock Sale -$351K -10K -4.63% $35.06 206K Jan 4, 2022 Direct F1, F2
transaction BLFS Common Stock Options Exercise $11K +7.86K +3.81% $1.40* 214K Jan 5, 2022 Direct
transaction BLFS Common Stock Sale -$269K -7.86K -3.67% $34.30 206K Jan 5, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -10K -56% $0.00 7.86K Jan 4, 2022 Common Stock 10K $1.40 Direct F4
transaction BLFS Employee Stock Option Options Exercise $0 -7.86K -100% $0.00* 0 Jan 5, 2022 Common Stock 7.86K $1.40 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 7, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.59 to $35.33, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $35.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 On February 15, 2012, the reporting person was granted an option to purchase 17,857 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.